Chlorthalidone in HFpEF
Chlorthalidone is not recommended as primary therapy for HFpEF but may be considered as adjunctive diuretic therapy for congestion management when loop diuretics alone are insufficient, or as an alternative in resource-limited settings where SGLT2 inhibitors are unavailable or unaffordable.
Primary Treatment Framework
Current guidelines prioritize SGLT2 inhibitors as the cornerstone pharmacotherapy for HFpEF (class I recommendation across the entire LVEF spectrum) 12. These agents reduce heart failure hospitalizations and improve quality of life, representing the evidence-based standard of care.
Role of Chlorthalidone in HFpEF
As Adjunctive Diuretic Therapy
For congestion management, thiazide-like diuretics including chlorthalidone should be reserved for patients who fail to respond adequately to loop diuretics 1. The 2022 AHA/ACC/HFSA guidelines specifically state that adding a thiazide to loop diuretic treatment should minimize electrolyte abnormalities and is recommended only when moderate- or high-dose loop diuretics prove insufficient 1.
The FDA label supports chlorthalidone use as adjunctive therapy in edema associated with congestive heart failure 3, though this predates modern HFpEF-specific evidence.
Evidence Supporting Chlorthalidone
The ALLHAT trial provides the strongest historical evidence: chlorthalidone significantly reduced new-onset hospitalized HFpEF compared with amlodipine (HR 0.69,95% CI 0.53-0.91, p=0.009), lisinopril (HR 0.74,95% CI 0.56-0.97, p=0.032), and doxazosin (HR 0.53,95% CI 0.38-0.73, p<0.001) 4. This occurred in high-risk hypertensive patients—a population overlapping substantially with HFpEF.
Recent acute care data shows chlorthalidone produces greater natriuretic response than spironolactone at 24 hours (p=0.009) and greater cumulative diuretic response (p=0.001) in AHF-pEF patients 5.
Clinical Algorithm for Chlorthalidone Use
When to Consider Chlorthalidone:
Primary scenario: Patient on loop diuretics with persistent congestion despite dose optimization
- Add chlorthalidone 12.5-25 mg once daily (maximum 100 mg) 1
- Monitor electrolytes closely given risk of hypokalemia and hyponatremia
Alternative scenario: Patient with HFpEF and hypertension with mild fluid retention who cannot access/afford SGLT2 inhibitors
Contraindicated: Severe renal disease, as chlorthalidone may precipitate azotemia 3
Critical Monitoring Parameters:
- Electrolytes: Particularly potassium and sodium (thiazides cause hypokalemia and hyponatremia)
- Renal function: Cumulative effects develop with impaired renal function 3
- Blood pressure: Avoid excessive hypotension
- Hepatic function: Use cautiously in liver disease as minor fluid/electrolyte shifts may precipitate hepatic coma 3
Important Caveats
Chlorthalidone lacks the non-diuretic benefits of SGLT2 inhibitors (metabolic effects, anti-inflammatory properties, cardiac remodeling) 6. It should not replace SGLT2 inhibitors as first-line therapy when available.
The evidence for chlorthalidone in HFpEF is primarily from prevention trials (ALLHAT) rather than treatment trials 4. Its role is symptom management through decongestion, not mortality reduction—unlike SGLT2 inhibitors which impact cardiovascular death and HF hospitalizations 2.
Duration of action (24-72 hours) makes chlorthalidone particularly useful for sustained diuresis 1, but this also increases risk of prolonged electrolyte disturbances requiring vigilant monitoring.
In patients with history of sulfonamide allergy or bronchial asthma, use with extreme caution given potential sensitivity reactions 3.